Bonti Announces Presentation Featuring EB-001A at Masters of Aesthetics Symposium

Bonti Announces Presentation Featuring EB-001A at Masters of Aesthetics Symposium

Dr. Jean Carruthers to Highlight Key Aesthetic Clinical Study Results for This Novel Neurotoxin with a Unique Clinical Profile

Bonti, a privately-held, clinical-stage biotechnology company, today announced a presentation featuring Phase 2a clinical results for its aesthetic product, EB-001A, at the 5th Annual Masters of Aesthetics Symposium on Friday, August 24th in San Diego, CA. Dr. Jean Carruthers, a globally-recognized cosmetic surgery expert who pioneered the cosmetic use of neurotoxins, will highlight topline results of Bonti’s aesthetic glabellar (frown) lines clinical trial and of SHINE-1, the first clinical trial in its SHINE (Scar Healing Improvement with Neurotoxin E) clinical program aimed at scar reduction. Dr. Carruthers will spotlight how these Phase 2a trials confirmed a favorable safety profile and suggested promising and differentiated clinical benefits.

EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a faster onset of action (within 24 hours) and a shorter duration of activity (2 to 4 weeks) compared to botulinum neurotoxin serotype A (BoNT/A) products. Considering the potential advantages of this profile, Bonti continues developing its product candidates EB-001A and EB-001T, for targeted aesthetic and therapeutic indications, respectively, in areas of unmet need with significant addressable market opportunities.

“We’re enthused and grateful Dr. Carruthers will be discussing the findings from the EB-001A clinical studies as part of her presentation at this exclusive conference,” remarked Fauad Hasan, CEO and co-founder at Bonti. “The audience will get to see exciting fast-onset results from our glabellar (frown) lines study and our recent SHINE-1 data, which suggest that EB-001A also has the potential to expedite the healing process and help physicians repair and improve outcomes of ‘cosmetically sensitive’ wounds.”

“As I’ve commented previously, the prospect of having EB-001A as a new injectable in our aesthetic toolbox for potential applications such as glabellar (frown) lines and scar reduction has a lot of value,” added Dr. Jean Carruthers, a Bonti Medical Advisor. “Bonti continues making expeditious progress in advancing the development of this unique neurotoxin and I remain hopeful it may be a new option to help produce improved patient outcomes for standout and additive botulinum neurotoxin uses in the future.”

SHINE Clinical Program
The SHINE (Scar Healing Improvement with Neurotoxin E) clinical program’s main objective is to support Bonti’s strategy to expand EB-001A’s potential aesthetic indications. This requires conducting multiple clinical trials, starting with the Phase 2a study, SHINE-1, in the Mohs surgery model.

About EB-001
Bonti is developing a first-in-class pipeline of proprietary product candidates based on EB-001, which is derived from botulinum neurotoxin serotype E (BoNT/E). BoNT/E has a validated mechanism of action similar to that of currently approved products derived from BoNT/A, but, based on preclinical and clinical data, BoNT/E has a faster onset of action (within 24 hours) and a shorter duration of activity (2 to 4 weeks) compared to BoNT/A products, which have an onset of action of approximately 3 to 7 days and a duration of activity of approximately 3 to 4 months. Based on this differentiated clinical profile, Bonti’s aesthetic product candidate, EB-001A, is being initially developed for glabellar frown lines and for scar reduction following Mohs surgery and Bonti’s therapeutic product candidate, EB-001T, is being developed for the treatment of focal muscle pain.

About Bonti
Bonti, based in Newport Beach, CA, is an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for aesthetic and therapeutic applications. The company was founded and is led by executives with extensive experience obtained at Allergan plc with botulinum neurotoxin products from discovery, clinical, supply chain, regulatory and commercialization perspectives. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti seeks to improve lives by successfully addressing key unmet needs in markets with significant addressable opportunities.

For more information, please visit http://bonti.com.

Contact
Orlando Rodrigues
Media Relations
orlando@bonti.com
760.212.5727

2018-08-23T18:32:21+00:00August 23rd, 2018|Press Releases|